Jeito logo.png
Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases
September 07, 2023 03:00 ET | Jeito Capital
Jeito Capital co-leads EUR 65 million (USD 711M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases Jeito Capital...
Jeito logo.png
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
March 07, 2023 04:00 ET | Jeito Capital
                                                             Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central...
Jeito logo.png
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma pour Noema Pharma, une biopharma ciblant les maladies graves du système nerveux central
March 07, 2023 04:00 ET | Jeito Capital
                                                             Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma ciblant les maladies graves du système...
Jeito logo.png
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars
December 06, 2022 07:00 ET | Jeito Capital
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...
Jeito logo.png
Jeito Capital investit dans CatalYm Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie
November 22, 2022 05:00 ET | Jeito Capital
Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie Jeito Capital co-dirige un financement de série C de 50 millions d'euros avec Brandon...
Jeito logo.png
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
November 22, 2022 05:00 ET | Jeito Capital
                                                            Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients...
Jeito logo.png
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies auto-immunes
November 01, 2022 09:05 ET | Jeito Capital
                                                            Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies...
Jeito logo.png
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
November 01, 2022 06:02 ET | Jeito Capital
                                                            Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with...
Jeito logo.png
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix
March 16, 2022 03:00 ET | Jeito Capital
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision...
Jeito logo.png
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)
September 20, 2021 01:00 ET | Jeito Capital
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)Jeito I exceeds target and becomes the largest European fund...